$10.8 Billion is the total value of Baker Brothers Advisors's 133 reported holdings in Q3 2015. The portfolio turnover from Q2 2015 to Q3 2015 was 21.4% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| INCY | Buy | Incyte Corporation | $2,148,673,000 | +38.7% | 19,474,969 | +31.0% | 19.85% | +46.1% |
| SGEN | Buy | Seattle Genetics, Inc. | $1,389,307,000 | -7.0% | 36,029,746 | +16.7% | 12.84% | -2.1% |
| ALXN | Alexion Pharmaceuticals, Inc. | $1,023,197,000 | -13.5% | 6,542,599 | 0.0% | 9.45% | -8.9% | |
| ABBV | AbbVie Inc. | $782,064,000 | -19.0% | 14,373,538 | 0.0% | 7.22% | -14.7% | |
| ACAD | ACADIA Pharmaceuticals Inc. | $677,321,000 | -21.0% | 20,481,442 | 0.0% | 6.26% | -16.8% | |
| Incyte Corporation Notes 1.25% 11/15/2020 144Aconv bonds | $598,696,000 | +5.4% | 274,500,000 | 0.0% | 5.53% | +11.1% | ||
| Incyte Corporation Notes 0.375% 11/15/2018 144Aconv bonds | $559,636,000 | +5.7% | 259,000,000 | 0.0% | 5.17% | +11.3% | ||
| ANAC | Buy | Anacor Pharmaceuticals, Inc. | $486,779,000 | +73.4% | 4,135,412 | +14.1% | 4.50% | +82.7% |
| BMRN | Sell | BioMarin Pharmaceutical Inc. | $429,321,000 | -23.4% | 4,076,353 | -0.5% | 3.97% | -19.3% |
| GHDX | Buy | Genomic Health Inc. | $289,011,000 | -23.9% | 13,658,328 | +0.0% | 2.67% | -19.8% |
| New | Clovis Oncology Inc. 2.5% 9/15/2021conv bonds | $215,311,000 | – | 129,300,000 | +100.0% | 1.99% | – | |
| DBVT | Buy | DBV Technologies S.A.sponsored adr | $194,393,000 | +250.6% | 5,462,019 | +193.3% | 1.80% | +269.5% |
| BCRX | Buy | BioCryst Pharmaceuticals, Inc. | $160,856,000 | -6.9% | 14,110,179 | +21.9% | 1.49% | -2.0% |
| DYAX | Sell | Dyax Corp. | $144,349,000 | -31.3% | 7,561,480 | -4.6% | 1.33% | -27.6% |
| BioMarin Pharmaceutical Inc. Notes 1.875% 4/23/2017conv bonds | $115,619,000 | -22.9% | 22,379,000 | 0.0% | 1.07% | -18.8% | ||
| MRTX | Buy | Mirati Therapeutics, Inc. | $101,714,000 | +15.2% | 2,955,074 | +5.3% | 0.94% | +21.4% |
| AQXP | Buy | Aquinox Pharmaceuticals, Inc. | $94,935,000 | +1042.4% | 6,747,332 | +463.5% | 0.88% | +1101.4% |
| Gilead, Inc. 1.625% 5/1/16conv bonds | $90,326,000 | -16.3% | 20,944,000 | 0.0% | 0.84% | -11.8% | ||
| HRTX | Buy | Heron Therapeutics, Inc. | $70,950,000 | -18.9% | 2,907,784 | +3.6% | 0.66% | -14.5% |
| CERS | Cerus Corporation | $61,532,000 | -12.5% | 13,553,275 | 0.0% | 0.57% | -7.9% | |
| BLCM | Bellicum Pharmaceuticals, Inc. | $60,889,000 | -31.7% | 4,190,594 | 0.0% | 0.56% | -28.0% | |
| Acorda Therapeutics, Inc. Notes 1.75% 6/15/2021conv bonds | $54,123,000 | -9.9% | 59,583,000 | 0.0% | 0.50% | -5.1% | ||
| ONCE | Spark Therapeutics, Inc. | $52,679,000 | -30.8% | 1,262,382 | 0.0% | 0.49% | -27.0% | |
| NVTA | Invitae Corporation | $47,327,000 | -51.5% | 6,554,967 | 0.0% | 0.44% | -48.9% | |
| VSAR | Sell | Versartis, Inc. | $37,378,000 | -28.5% | 3,241,783 | -5.7% | 0.34% | -24.8% |
| IMGN | Buy | ImmunoGen, Inc. | $34,061,000 | +2.1% | 3,548,040 | +52.9% | 0.32% | +7.5% |
| NBIX | Buy | Neurocrine Biosciences, Inc. | $29,872,000 | +15.3% | 750,739 | +38.5% | 0.28% | +21.6% |
| INSM | Insmed, Inc. | $29,405,000 | -24.0% | 1,583,490 | 0.0% | 0.27% | -19.8% | |
| ACOR | Buy | Acorda Therapeutics, Inc. | $29,078,000 | +18.1% | 1,096,876 | +48.4% | 0.27% | +24.5% |
| MDVN | New | Medivation, Inc. | $28,039,000 | – | 659,752 | +100.0% | 0.26% | – |
| HALO | Halozyme Therapeutics, Inc. | $25,934,000 | -40.5% | 1,931,057 | 0.0% | 0.24% | -37.2% | |
| PGNX | Progenics Pharmaceuticals, Inc. | $24,887,000 | -23.3% | 4,350,808 | 0.0% | 0.23% | -19.3% | |
| GILD | Gilead Sciences, Inc. | $24,547,000 | -16.1% | 249,995 | 0.0% | 0.23% | -11.7% | |
| ITCI | Buy | Intra-Cellular Therapies, Inc. | $24,391,000 | +632.9% | 609,166 | +484.8% | 0.22% | +675.9% |
| ZGNX | New | Zogenix, Inc. | $24,278,000 | – | 1,798,365 | +100.0% | 0.22% | – |
| New | Exelisis, Inc. Notes 4.25% 8/15/2019conv bonds | $23,988,000 | – | 20,000,000 | +100.0% | 0.22% | – | |
| LIFE | aTyr Pharma Inc. | $23,958,000 | -44.6% | 2,335,125 | 0.0% | 0.22% | -41.7% | |
| IDRA | Buy | Idera Pharmaceuticals, Inc. | $23,370,000 | -9.6% | 6,976,162 | +0.1% | 0.22% | -4.8% |
| XNPT | XenoPort, Inc. | $22,585,000 | -43.4% | 6,508,622 | 0.0% | 0.21% | -40.3% | |
| CPRX | Catalyst Pharmaceuticals, Inc. | $22,007,000 | -27.4% | 7,335,692 | 0.0% | 0.20% | -23.7% | |
| SGMO | Buy | Sangamo BioSciences, Inc. | $21,183,000 | -40.9% | 3,755,876 | +16.2% | 0.20% | -37.6% |
| TGTX | TG Therapeutics, Inc. | $20,200,000 | -39.2% | 2,003,991 | 0.0% | 0.19% | -36.0% | |
| New | Aegerion Pharmaceuticals, Inc. Notes 2.0% 8/15/2019conv bonds | $19,873,000 | – | 26,517,000 | +100.0% | 0.18% | – | |
| ARRY | Sell | Array BioPharma Inc. | $19,657,000 | -50.3% | 4,310,666 | -21.4% | 0.18% | -47.6% |
| CLVS | Clovis Oncology, Inc. | $18,634,000 | +4.6% | 202,630 | 0.0% | 0.17% | +10.3% | |
| ALDR | Sell | Alder Biopharmaceuticals Inc. | $16,820,000 | -64.4% | 513,439 | -42.4% | 0.16% | -62.6% |
| DSCI | Derma Sciences, Inc. | $16,286,000 | -34.2% | 3,457,841 | 0.0% | 0.15% | -30.9% | |
| BioMarin Pharmaceutical Inc. Notes 0.75% 10/15/2018conv bonds | $15,899,000 | -16.1% | 12,228,000 | 0.0% | 0.15% | -11.4% | ||
| NVAX | Buy | Novavax, Inc. | $15,524,000 | -28.4% | 2,195,687 | +12.8% | 0.14% | -24.7% |
| FOMX | Foamix Pharmaceuticals Ltd. | $15,004,000 | -28.5% | 2,046,967 | 0.0% | 0.14% | -24.5% | |
| GLPG | Galapagos NV ADRspon adr | $15,033,000 | -21.0% | 369,276 | 0.0% | 0.14% | -16.8% | |
| RPRX | Repros Therapeutics Inc. | $14,533,000 | +3.9% | 1,955,944 | 0.0% | 0.13% | +8.9% | |
| PRQR | ProQR Therapeutics N.V. | $14,400,000 | -12.6% | 988,299 | 0.0% | 0.13% | -8.3% | |
| ACHN | Buy | Achillion Pharmaceuticals, Inc. | $13,820,000 | +2.4% | 2,000,000 | +31.3% | 0.13% | +8.5% |
| ZFGN | Buy | Zafgen, Inc. | $12,472,000 | +25.2% | 390,346 | +35.7% | 0.12% | +32.2% |
| BLUE | Sell | bluebird bio, Inc. | $12,072,000 | -52.6% | 141,105 | -6.6% | 0.11% | -49.8% |
| RARE | Ultragenyx Pharmaceuticals | $11,932,000 | -5.9% | 123,894 | 0.0% | 0.11% | -0.9% | |
| THLD | Threshold Pharmaceuticals, Inc. | $11,907,000 | +0.7% | 2,925,519 | 0.0% | 0.11% | +5.8% | |
| LJPC | La Jolla Pharmaceutical Company | $11,450,000 | +13.4% | 412,008 | 0.0% | 0.11% | +19.1% | |
| XNCR | Xencor, Inc. | $10,665,000 | -44.3% | 872,072 | 0.0% | 0.10% | -41.1% | |
| LBIO | Lion Biotechnologies, Inc. | $10,468,000 | -37.2% | 1,817,429 | 0.0% | 0.10% | -33.6% | |
| ADHD | Sell | Alcobra Ltd. | $9,905,000 | -15.4% | 1,639,871 | -8.4% | 0.09% | -10.7% |
| AKTX | New | Akari Therapeutics PLC ADRsponsored adr | $9,499,000 | – | 395,882 | +100.0% | 0.09% | – |
| CNCE | Concert Pharmaceuticals, Inc. | $9,308,000 | +26.1% | 495,908 | 0.0% | 0.09% | +32.3% | |
| OSIR | Osiris Therapeutics, Inc. | $9,220,000 | -5.1% | 499,193 | 0.0% | 0.08% | 0.0% | |
| GBT | New | Global Blood Therapeutics, Inc. | $8,432,000 | – | 200,000 | +100.0% | 0.08% | – |
| ASND | Buy | Ascendis Pharma A/Ssponsored adr | $7,709,000 | +336.0% | 435,540 | +335.5% | 0.07% | +343.8% |
| MGNX | Buy | MacroGenics, Inc. | $7,449,000 | -35.7% | 347,776 | +14.0% | 0.07% | -32.4% |
| AGIO | Agios Pharmaceuticals, Inc. | $7,059,000 | -36.5% | 100,000 | 0.0% | 0.06% | -33.0% | |
| DERM | Buy | Dermira, Inc. | $6,419,000 | +265.8% | 275,000 | +175.0% | 0.06% | +293.3% |
| AIMT | New | Aimmune Therapeutics, Inc. | $6,330,000 | – | 250,000 | +100.0% | 0.06% | – |
| LGND | Ligand Pharmaceuticals Incorporated | $6,286,000 | -15.1% | 73,386 | 0.0% | 0.06% | -10.8% | |
| Buy | NeuroDerm Ltd. | $6,304,000 | +64.3% | 305,000 | +22.0% | 0.06% | +70.6% | |
| ECYT | New | Endocyte, Inc. | $6,213,000 | – | 1,356,552 | +100.0% | 0.06% | – |
| ARWR | Arrowhead Research Corp. | $5,815,000 | -19.4% | 1,009,509 | 0.0% | 0.05% | -14.3% | |
| AERI | Aerie Pharmaceuticals, Inc. | $5,311,000 | +0.5% | 299,356 | 0.0% | 0.05% | +6.5% | |
| RXDX | Ignyta, Inc. | $5,013,000 | -41.8% | 571,000 | 0.0% | 0.05% | -39.5% | |
| TRVN | New | Trevena, Inc. | $4,658,000 | – | 450,000 | +100.0% | 0.04% | – |
| SAGE | Sage Therapeutics, Inc. | $4,444,000 | -42.0% | 105,000 | 0.0% | 0.04% | -38.8% | |
| CMRX | Chimerix, Inc. | $4,401,000 | -17.3% | 115,216 | 0.0% | 0.04% | -12.8% | |
| AMRN | Amarin Corporation plcspons adr new | $4,257,000 | -21.5% | 2,205,710 | 0.0% | 0.04% | -18.8% | |
| DNAI | New | Pronai Therapeutics, Inc. | $4,104,000 | – | 200,000 | +100.0% | 0.04% | – |
| CRIS | Buy | Curis, Inc. | $4,039,000 | +13.2% | 1,999,303 | +85.5% | 0.04% | +19.4% |
| PRTO | Buy | Proteon Therapeutics, Inc. | $3,820,000 | +21.0% | 274,617 | +55.4% | 0.04% | +25.0% |
| MCRB | Seres Therapeutics, Inc. | $3,705,000 | -28.6% | 125,000 | 0.0% | 0.03% | -26.1% | |
| OMER | Sell | Omeros Corporation | $3,685,000 | -78.8% | 336,226 | -65.1% | 0.03% | -77.6% |
| NBRV | New | Nabriva Therapeutics AGsponsored adr | $3,325,000 | – | 350,000 | +100.0% | 0.03% | – |
| JUNO | Juno Therapeutics, Inc. | $3,255,000 | -23.7% | 80,000 | 0.0% | 0.03% | -18.9% | |
| CYTR | CytRx Corporation | $3,128,000 | -36.3% | 1,319,989 | 0.0% | 0.03% | -32.6% | |
| EPZM | Epizyme, Inc. | $2,990,000 | -46.4% | 232,481 | 0.0% | 0.03% | -42.9% | |
| Array BioPharma Inc. Notes 3.0% 6/1/2020conv bonds | $2,921,000 | -22.7% | 3,000,000 | 0.0% | 0.03% | -18.2% | ||
| STML | Stemline Therapeutics, Inc. | $2,945,000 | -25.0% | 333,497 | 0.0% | 0.03% | -20.6% | |
| NTRA | New | Natera, Inc. | $2,713,000 | – | 250,000 | +100.0% | 0.02% | – |
| ENTA | Enanta Pharmaceuticals, Inc. | $2,723,000 | -19.7% | 75,357 | 0.0% | 0.02% | -16.7% | |
| MSTX | Mast Therapeutics, Inc. | $2,730,000 | +18.3% | 4,707,464 | 0.0% | 0.02% | +25.0% | |
| SNSS | Sunesis Pharmaceuticals, Inc. | $2,592,000 | -73.1% | 3,200,000 | 0.0% | 0.02% | -71.4% | |
| AFMD | Affimed N.V. | $2,468,000 | -54.2% | 400,000 | 0.0% | 0.02% | -51.1% | |
| Protalix BioTherapeutics, Inc. Notes 4.5% 9/15/18conv bonds | $2,450,000 | -6.0% | 3,423,000 | 0.0% | 0.02% | 0.0% | ||
| ASMB | Assembly Biosciences, Inc. | $2,390,000 | -50.4% | 250,000 | 0.0% | 0.02% | -47.6% | |
| KPTI | Karyopharm Therapeutics Inc. | $2,285,000 | -61.3% | 216,990 | 0.0% | 0.02% | -59.6% | |
| ISIS | Isis Pharmaceuticals, Inc. | $2,310,000 | -29.7% | 57,140 | 0.0% | 0.02% | -27.6% | |
| VTAE | Vitae Pharmaceuticals, Inc. | $2,065,000 | -23.5% | 187,597 | 0.0% | 0.02% | -20.8% | |
| AUPH | Aurinia Pharmaceuticals Inc. | $1,999,000 | -6.2% | 711,499 | 0.0% | 0.02% | -5.3% | |
| BLPH | Buy | Bellerophon Therapeutics, Inc. | $1,832,000 | -34.0% | 352,928 | +0.8% | 0.02% | -29.2% |
| DVAX | New | Dynavax Technologies Corporation | $1,841,000 | – | 75,000 | +100.0% | 0.02% | – |
| IMDZ | Immune Design Corp. | $1,817,000 | -40.9% | 148,937 | 0.0% | 0.02% | -37.0% | |
| IRWD | Ironwood Pharmaceuticals, Inc. | $1,763,000 | -13.6% | 169,163 | 0.0% | 0.02% | -11.1% | |
| LOXO | Loxo Oncology, Inc. | $1,748,000 | -3.1% | 100,000 | 0.0% | 0.02% | 0.0% | |
| MDWD | MediWound Ltd. | $1,717,000 | +7.9% | 225,000 | 0.0% | 0.02% | +14.3% | |
| MRNS | Marinus Pharmaceuticals, Inc. | $1,668,000 | -28.1% | 200,000 | 0.0% | 0.02% | -25.0% | |
| PTN | Palatin Technologies, Inc. | $1,661,000 | -9.0% | 2,050,000 | 0.0% | 0.02% | -6.2% | |
| OPHT | Ophthotech Corporation | $1,444,000 | -22.2% | 35,649 | 0.0% | 0.01% | -18.8% | |
| CLLS | Cellectis S.A.sponsored ads | $1,318,000 | -26.9% | 50,000 | 0.0% | 0.01% | -25.0% | |
| TENX | Buy | Tenax Therapeutics Inc. | $1,260,000 | -3.9% | 420,000 | +18.2% | 0.01% | +9.1% |
| BDSI | BioDelivery Sciences International, Inc. | $1,168,000 | -30.1% | 210,021 | 0.0% | 0.01% | -26.7% | |
| ADAP | Adaptimmune Therapeutics plc ADRsponds adr | $1,197,000 | -34.7% | 100,000 | 0.0% | 0.01% | -31.2% | |
| DSCO | Discovery Laboratories, Inc. | $1,071,000 | -55.9% | 3,569,643 | 0.0% | 0.01% | -52.4% | |
| ABUS | New | Arbutus Biopharma Corporation | $1,100,000 | – | 180,582 | +100.0% | 0.01% | – |
| OHRP | Ohr Pharmaceuticals, Inc. | $1,022,000 | +9.9% | 370,370 | 0.0% | 0.01% | +12.5% | |
| RTTR | Ritter Pharmaceuticals, Inc. | $820,000 | -53.9% | 400,000 | 0.0% | 0.01% | -50.0% | |
| New | Trillium Therapeutics, Inc. | $821,000 | – | 63,014 | +100.0% | 0.01% | – | |
| ALDX | Aldeyra Therapeutics, Inc. | $828,000 | -24.9% | 142,000 | 0.0% | 0.01% | -20.0% | |
| ALNY | Alnylam Pharmaceuticals, Inc. | $911,000 | -33.0% | 11,340 | 0.0% | 0.01% | -33.3% | |
| XLRN | Acceleron Pharma, Inc. | $716,000 | -21.3% | 28,765 | 0.0% | 0.01% | -12.5% | |
| QURE | UniQure B.V. | $614,000 | -24.2% | 30,000 | 0.0% | 0.01% | -14.3% | |
| AKAOQ | Achaogen, Inc. | $576,000 | -4.5% | 100,000 | 0.0% | 0.01% | 0.0% | |
| FMI | Foundation Medicine, Inc. | $385,000 | -45.5% | 20,892 | 0.0% | 0.00% | -33.3% | |
| CCXI | ChemoCentryx, Inc. | $297,000 | -26.5% | 49,064 | 0.0% | 0.00% | -25.0% | |
| FPRX | Five Prime Therapeutics, Inc. | $296,000 | -38.1% | 19,247 | 0.0% | 0.00% | -25.0% | |
| SGYPQ | New | Synergy Pharmaceuticals, Inc. | $356,000 | – | 67,100 | +100.0% | 0.00% | – |
| CYCCP | Cyclacel Pharmaceuticals, Inc. Pfd. Conv. Ex 6%pfd conv ex 6% | $62,000 | -27.1% | 13,253 | 0.0% | 0.00% | 0.0% | |
| Aptose Biosciences, Inc. | $144,000 | -15.3% | 33,397 | 0.0% | 0.00% | 0.0% | ||
| BTXWS | BioTime, Inc. Rights*w exp 10/01/201 | $17,000 | -26.1% | 20,084 | 0.0% | 0.00% | – | |
| BOTA | Exit | Biota Pharmaceuticals, Inc. | $0 | – | -830,440 | -100.0% | -0.02% | – |
| TKMR | Exit | Tekmira Pharmaceuticals Corp. | $0 | – | -180,582 | -100.0% | -0.02% | – |
| ZIOP | Exit | ZIOPHARM Oncology, Inc. | $0 | – | -189,259 | -100.0% | -0.02% | – |
| RCPT | Exit | Receptos, Inc. | $0 | – | -23,900 | -100.0% | -0.04% | – |
| VNDA | Exit | Vanda Pharmaceuticals Inc. | $0 | – | -409,881 | -100.0% | -0.05% | – |
| ZGNX | Exit | Zogenix, Inc. | $0 | – | -10,028,564 | -100.0% | -0.15% | – |
| KYTH | Exit | Kythera Biopharmaceuticals, Inc. | $0 | – | -387,741 | -100.0% | -0.26% | – |
| XOMA | Exit | XOMA Corporation | $0 | – | -14,683,513 | -100.0% | -0.50% | – |
| Exit | Medivation, Inc. 2.625% 4/1/17conv bonds | $0 | – | -33,889,000 | -100.0% | -0.66% | – | |
| Exit | Incyte Corporation Notes 4.75% 10/1/2015 144Aconv bonds | $0 | – | -40,446,000 | -100.0% | -4.20% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2015-11-16
About Baker Brothers Advisors
Baker Brothers Advisors is a well-known investment management firm that specializes in the healthcare sector. The firm was founded in 2000 by brothers Julian and Felix Baker, who are both highly respected in the industry. Julian Baker is the CEO of the firm, while Felix Baker serves as a managing partner.
Baker Brothers Advisors has a reputation for investing in innovative healthcare companies that have the potential to make a significant impact on the industry. The firm has a long-term investment approach and is known for taking large positions in companies that it believes in. Some of the firm's most successful investments include companies such as Pharmacyclics, which was acquired by AbbVie for $21 billion, and Ariad Pharmaceuticals, which was acquired by Takeda for $5.2 billion.
The firm's investment strategy is led by its Chief Investment Officer, Dr. Robert Duggan, who has a background in both medicine and finance. Dr. Duggan is known for his ability to identify promising healthcare companies and for his willingness to take risks on early-stage companies.
Overall, Baker Brothers Advisors is a highly respected investment management firm that has a proven track record of success in the healthcare sector. While the firm's investment approach may not be suitable for all investors, those who are interested in the healthcare sector may want to consider Baker Brothers Advisors as a potential investment opportunity.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Incyte Corporation | 42 | Q3 2023 | 37.6% |
| ACADIA Pharmaceuticals Inc. | 42 | Q3 2023 | 10.9% |
| Biomarin Pharmaceuticals Inc. | 42 | Q3 2023 | 5.9% |
| BioCryst Pharmaceuticals, Inc. | 42 | Q3 2023 | 1.7% |
| Cerus Corporation | 42 | Q3 2023 | 0.9% |
| Insmed Incorporated | 42 | Q3 2023 | 0.4% |
| Mirati Therapeutics, Inc. | 41 | Q3 2023 | 1.8% |
| Bluebird Bio Inc. | 41 | Q3 2023 | 0.3% |
| Heron Therapeutics, Inc. | 39 | Q3 2023 | 1.5% |
| ChemoCentryx, Inc. | 37 | Q3 2022 | 0.6% |
View Baker Brothers Advisors's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Neoleukin Therapeutics, Inc. | August 17, 2023 | 9,469,838 | 20.0% |
| Mereo Biopharma Group plc | August 10, 2023 | 14,604,391 | 2.2% |
| Verastem, Inc. | August 10, 2023 | ? | ? |
| TScan Therapeutics, Inc. | June 02, 2023 | 2,793,938 | 6.5% |
| ACADIA PHARMACEUTICALS INC | May 24, 2023 | 43,084,280 | 26.5% |
| INCYTE CORP | March 15, 2023 | 36,280,967 | 16.3% |
| Seagen Inc. | March 13, 2023 | 46,985,656 | 25.1% |
| Talis Biomedical Corp | March 10, 2023 | 37,569,140 | 66.2% |
| Aeglea BioTherapeutics, Inc. | February 14, 2023 | 6,384,013 | 9.9% |
| Merus N.V. | February 14, 2023 | ? | ? |
View Baker Brothers Advisors's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-04-23 |
| SC 13D/A | 2024-04-23 |
| 4 | 2024-04-22 |
| 3 | 2024-04-18 |
| SC 13D | 2024-04-18 |
| 3 | 2024-04-01 |
| 4 | 2024-04-01 |
| 4 | 2024-04-01 |
| 4 | 2024-04-01 |
| SC 13D | 2024-04-01 |
View Baker Brothers Advisors's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.